Effect of Nano-curcumin on insulin resistance and serum levels of Afamin in patients with metabolic syndrome

Effect of Nano-curcumin on insulin resistance and serum levels of Afamin in patients with metabolic syndrome: a before-after clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N277

Enrollment

Registered

2019-05-13

Start date

2019-03-06

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome. Metabolic syndrome

Interventions

Intervention 1: Intervention group: Tablet Nano-curcumin 80 mg/day for 2 months. Intervention 2: Control group: In comparison with before intervention.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years Metabolic syndrome

Exclusion criteria

Exclusion criteria: Diabetes Thyroid disease Liver disease Renal disease

Design outcomes

Primary

Measure	Time frame
Measuring the serum levels of Afamin. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: Through laboratory test.;Measuring the serum levels of insulin. Timepoint: Before the intervention and 2 months after the intervention. Method of measurement: Through laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Khodamoradi

Hamedan University of Medical Sciences

khodamoradizahra@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026